跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 68 条关于
“CDKN2B”
全部
68
临床试验
21
药物
34
机构
0
资讯
13
去年
Cyclacel Completes Enrollment in Fadraciclib Trial for Tumors with CDKN2A/B Abnormalities
8个月前
CATNON Trial Final Results Confirm Adjuvant Temozolomide Benefit in IDH-Mutant Anaplastic Glioma
去年
Insilico Medicine Develops Novel AI-Designed CDK12/13 Inhibitors for Treatment-Resistant Cancers
去年
Carrick Therapeutics Initiates Phase 1 Trial of Novel CDK12/13 Inhibitor CT7439 in Advanced Solid Tumors
5个月前
Gilead Exercises Option for Kymera's KT-200 CDK2 Degrader, Triggering $45M Milestone Payment
去年
Gilead and Kymera Partner on Novel CDK2 Molecular Glue Degrader for Cancer Treatment
去年
Novel CDK2 Inhibitor INX-315 Shows Promise in Overcoming Cancer Drug Resistance, Study Reveals
9个月前
Avenzo's CDK2 Inhibitor AVZO-021 Shows Promising Activity in Breast and Ovarian Cancer Patients
4个月前
Avenzo Therapeutics Initiates CDK4/CDK2 Dual Inhibitor Combination Trial for HR+/HER2- Breast Cancer
去年
MSK Research: CDK2 Inhibition Overcomes Breast Cancer Drug Resistance, 177Lu-PSMA-617 Shows Promise in Prostate Cancer
第 1 页,共 2 页
上一页
下一页